Immunotherapy for Infectious Diseases

Host Cell-Directed Approaches 233
43. Flexnor C, Barditch-Crovo PA, Kornhauser DM. Pharmacokinetics, toxicity, and activity
of intravenous dextran sulfate in human immunodeficiency infection. Antimicrob Agents
Chemother 1991; 35:2544–2550.
44. Cocchi F, Devico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of
RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced
by CD8� T cells. Science 1995; 270:1811–1815.
45. Pal R, Garzino-Demo A, Markham PD, et al. Inhibition of HIV-1 infection by the beta
chemokine MDC. Science 1997; 278:695–698.
46. Arenzana-Seisedos F, Virelizier JL, Rousset D. HIV blocked by chemokine antagonist.
Nature 1996; 383:400.
47. Simmons G, Clapham PR, Picard L. Potent inhibition of HIV-1 infectivity in macrophages
and lymphocytes by a novel CCR5 antagonist. Science 1997; 276:276–279.
48. Dragic T, Litwin V, Allaway GP, et al. HIV-1 entry into CD4� cells is mediated by the
chemokine receptor CC-CKR-5. Nature 1996; 381:667–673.
49. Deng H, Liu R, Ellmeier W, et al. Identification of a major co-receptor for primary isolates
of HIV-1. Nature 1996; 381:661–666.
50. Oberlin E, Amara A, Bachelerie, F, et al. The CXC chemokine SDF-1 is the ligand for
LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 1996;
382:833–835.
51. Bleul CC, Farzan M, Choe H, et al. The lymphocyte chemoattractant SDF-1 is a ligand
for LESTR/fusin and blocks HIV-1 entry. Nature 1996; 382:829–833.
52. Derdeyn CA, Costello C, Kilby JM, et al. Correlation between circulating SDF-1 levels
and CD4 cell count in human immunodeficiency virus type-1 infected individuals. AIDS
Res Hum Retroviruses 1999; 15:1063–1071.
53. Chen JD, Bai X, Yang AG. Inactivation of HIV-1 chemokine co-receptor CXCR-4 by a
novel intrakine strategy. Nat Med 1997; 3:1110–1116.
54. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression
to AIDS by a deletion allele of the CKR5 structural gene. Science 1996;
273:1856–1862.
55. Nagasawa T, Hirota S, Tachibana K, et al. Defects of B-cell lymphopoiesis and bonemarrow
myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 1996;
382:635–638.
56. Klausner JD, Makonkawkeyoon L, Akarasewi P, et al. The effect of thalidomide on the
pathogenesis of HIV-1 and M. tuberculosis infection. J Acquir Immun Defic Syndr Hum
Retrovirol 1996; 11:247–257.
57. Donzella G, Schols D, Lin S. AMD3100, a small molecule inhibitor of HIV-1 entry via
the CXCR4 co-receptor. Nat Med 1998; 4:72–77.
58. Murakami T, Nakajima T, Koyanagi Y. A small molecule CXCR4 inhibitor that blocks
T cell line-tropic HIV-1 infection. J Exp Med 1997; 186:1389–1393.
59. Arakaki R, Tamamaura H, Premanathan M. T134, a small-molecule CXCR4 inhibitor, has
no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure.
J Virol 1999; 73:1719–1723.
60. Wild C, Greenwell T, Matthews T. A synthetic peptide from HIV-1 gp41 is a potent
inhibitor of virus-mediated cell-cell fusion. Aids Res Hum Retroviruses 1993; 9:1051–1053.
61. Lalezari J, Eron J, Carlson M. Safety, pharmacokinetics, and antiviral activity of T-20 as
a single agent in heavily pre-treated patients. In: 6th Conference on Retroviruses and
Opportunistic Infections, 1999 (Abstract LB13).
62. Rimsky LT, Shugar DC, Matthews T. Determinants of HIV-1 resistance to gp41-derived
inhibitory peptides. J Virol 1998; 72:986–992.
63. Wei X, Kilby JM, Hopkins S, Saag MS, Shaw G. HIV-1 selection in response to inhibition
of virus fusion and entry. In: 6th Conference on Retroviruses and Opportunistic Infections,
1999 (Abstract 611).